Work

Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)

Year: 2022

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood-2022-163027

Authors: Sameem Abedin, Mehdi Hamadani, Shernan G Holtan, Gary J. Schiller, Molly Gallogly, Edmund K. Waller, Satyajit Kosuri, Sunil H Abhyankar, Sarah M. Anand, Mahasweta Gooptu, Iming Cho, Simona Reed, Shih-Yao Lin, Jesse W Hall, Paul J Martin

Institutions: Medical College of Wisconsin, University of Minnesota, University of California, Los Angeles, University Hospitals Seidman Cancer Center, Emory University, Winship Cancer Institute, University of Chicago Medical Center, The University of Kansas Cancer Center, University of Michigan, Dana-Farber Cancer Institute, Fred Hutch Cancer Center

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310112142

FWCI: 1.249

Cites:

Cited by: 8

Related to: 10